(IJRMST) 2016, Vol. No. 1, Jan-Jun **e-ISSN: 2455-5134, p-ISSN: 2455-9059**

DEVELOPMENT AND CHARACTERIZATION OF COLON SPECIFIC NOVEL DRUG DELIVERY SYSTEM FOR THE TREATMENT OF COLORECTOL CANCER

***Saurabh Bhargava, **Dr. Ashutosh Mishra**
**Research Scholar,*
***Research Supervisor,*
Department of Pharmacy,
Himalayan University,
Itanagar, Arunachal Pradesh

ABSTRACT

Colorectal cancer (CRC) is a significant health issue worldwide, often necessitating advanced treatment modalities. Traditional drug delivery systems frequently fail to effectively target the colon, leading to suboptimal therapeutic outcomes. This paper discusses the development and characterization of a novel colon-specific drug delivery system designed to enhance the therapeutic efficacy of colorectal cancer treatments. The system utilizes advanced polymeric carriers and targeting mechanisms to ensure drug release specifically at the site of the tumor. This approach aims to maximize therapeutic impact while minimizing systemic side effects.

KEYWORDS: *Chitosan, Drug Encapsulation, Targeted Drug Delivery, Controlled Release, In Vitro Release Studies.*

INTRODUCTION

Colorectal cancer (CRC) is a major global health concern and ranks among the leading causes of cancer-related morbidity and mortality. It arises from the epithelial cells of the colon or rectum and often presents at advanced stages, complicating treatment and decreasing overall survival rates. Traditional treatment strategies, including surgery, chemotherapy, and radiation therapy, while effective, are often hampered by limitations such as non-specific drug delivery, systemic toxicity, and suboptimal therapeutic efficacy. These challenges underscore the urgent need for advanced therapeutic approaches that offer targeted delivery and enhanced treatment outcomes.

One of the most promising strategies in improving the treatment of CRC is the development of novel drug delivery systems (DDS) that specifically target the colon. Traditional drug delivery methods often face issues of premature drug release in the upper gastrointestinal tract, leading to reduced therapeutic efficacy and increased side effects. To address these challenges, researchers have focused on designing colon-specific drug delivery systems that release therapeutic agents directly at the site of the tumor, minimizing systemic exposure and enhancing drug bioavailability at the target site.

Colon-specific DDS aim to ensure that drugs are released only upon reaching the colon, thereby improving the precision of treatment. This specificity is particularly important for colorectal

cancer, where the goal is to deliver high concentrations of the drug directly to the tumor while avoiding damage to healthy tissues. Various approaches have been explored to achieve this colon-specific delivery, including the use of polymeric carriers that can withstand the harsh conditions of the stomach and small intestine, and only degrade in the colonic environment.

Polymeric carriers have emerged as a highly effective platform for colon-specific drug delivery. These carriers, often composed of biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA) and chitosan, can be engineered to provide controlled and sustained drug release. PLGA, a well-established polymer in drug delivery, offers excellent biocompatibility and controlled degradation properties. Chitosan, derived from chitin, provides additional benefits such as mucoadhesive properties and biodegradability, which enhance drug retention and release in the colon.

The development of drug-loaded polymeric microparticles involves the encapsulation of chemotherapeutic agents, such as 5-fluorouracil (5-FU) and oxaliplatin, within these polymers. These drugs are commonly used in the treatment of colorectal cancer due to their efficacy in inhibiting cancer cell proliferation. The encapsulation process ensures that the drugs are protected from premature degradation and are released specifically in the colonic environment. This is achieved through various techniques, including solvent evaporation and coacervation, which help in achieving the desired particle size and drug loading efficiency.

Incorporating targeting ligands into the polymeric carriers further enhances the specificity of the drug delivery system. Ligands such as folic acid, which is known to bind specifically to colorectal cancer cells, can be conjugated to the polymeric matrix. This targeted approach ensures that the drug is preferentially delivered to cancerous tissues, thereby improving therapeutic efficacy and reducing off-target effects.

The characterization of these novel DDS involves a comprehensive evaluation of their physicochemical properties, including particle size, surface morphology, and drug loading efficiency. Techniques such as scanning electron microscopy (SEM) provide insights into the structural characteristics of the microparticles, while in vitro release studies simulate gastrointestinal conditions to assess drug release profiles. These studies are crucial for understanding the behavior of the DDS in different pH environments and ensuring that the drug is released predominantly in the colon.

In vivo studies are essential for evaluating the practical effectiveness of the DDS. These studies assess the biodistribution of the drug, pharmacokinetics, and therapeutic outcomes in animal models of colorectal cancer. The goal is to confirm that the DDS delivers the drug effectively to the tumor site, achieves the desired therapeutic effect, and minimizes systemic toxicity.

The development of colon-specific DDS represents a significant advancement in the field of cancer therapy. By focusing on the specific needs of colorectal cancer treatment, these systems offer a tailored approach that improves drug delivery precision, enhances therapeutic outcomes, and reduces adverse effects. The integration of advanced polymeric carriers and targeting

strategies marks a promising step forward in addressing the limitations of traditional treatment methods and provides a foundation for future research and clinical applications.

In the evolution of novel drug delivery systems for colon-specific treatment highlights the potential to revolutionize colorectal cancer therapy. The ability to deliver drugs directly to the tumor site while minimizing systemic exposure is a crucial advancement that holds promise for improving patient outcomes and reducing the burden of this prevalent disease. Continued research and development in this area will be essential in translating these innovations into effective clinical therapies that can make a meaningful difference in the lives of patients with colorectal cancer.

PREPARATION OF DRUG-LOADED POLYMERIC MICROPARTICLES

1. **Selection of Materials**: Choose appropriate polymers, such as poly(lactic-co-glycolic acid) (PLGA) or chitosan, for microparticle formulation. Select drugs (e.g., 5-fluorouracil, oxaliplatin) based on their therapeutic efficacy for colorectal cancer.

2. **Drug Encapsulation**: Dissolve the polymer and drug in a volatile organic solvent (e.g., dichloromethane). Prepare a water phase containing a stabilizer (e.g., polyvinyl alcohol). Emulsify the polymer-drug solution in the water phase using a high-speed homogenizer. Dissolve the polymer and drug in a suitable solvent. Add a precipitant to induce phase separation, forming coacervates that encapsulate the drug.

3. **Microparticle Formation**: Remove the solvent through evaporation or dialysis to form solid microparticles.

4. **Particle Collection and Drying**: Centrifuge the mixture to collect microparticles. Wash with water to remove residual solvents and stabilizers. Dry the collected particles under vacuum or using a freeze dryer.

5. **Characterization**: Assess particle size, morphology, and drug loading efficiency using techniques such as scanning electron microscopy (SEM) and high-performance liquid chromatography (HPLC).

INCORPORATION OF TARGETING LIGANDS

Selection of Ligands: Choose ligands that specifically bind to receptors overexpressed in colorectal cancer cells, such as folic acid or antibodies targeting cancer cell surface markers.

Ligand-Conjugation to Polymers:

- **Chemical Conjugation**: Activate the polymer surface to introduce reactive groups (e.g., carboxyl or amine groups). Conjugate the ligand to these reactive sites using covalent bonding techniques, such as carbodiimide coupling or maleimide-thiol chemistry.

- **Physical Adsorption**: Alternatively, physically adsorb ligands onto the surface of pre-formed polymeric microparticles through electrostatic or hydrophobic interactions.

Integration During Microparticle Formation: For polymers that allow ligand incorporation during synthesis:

- **Mixing During Encapsulation**: Add the targeting ligand to the polymer-drug solution before microparticle formation, allowing the ligand to be incorporated throughout the particle matrix.

- **Co-precipitation**: Include the ligand in the solution used for coacervation or other particle formation methods, ensuring uniform distribution within the particles.

Verification of Ligand Presence: Confirm successful ligand incorporation and functional activity through techniques like enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), or fluorescence labeling.

Functional Testing: Evaluate the binding efficiency of the ligand-coated microparticles to colorectal cancer cells in vitro to ensure effective targeting. This step is crucial for validating the specificity and efficacy of the targeting strategy.

CONCLUSION

The development and characterization of a colon-specific novel drug delivery system for the treatment of colorectal cancer represent a promising advancement in targeted therapy. By focusing drug release specifically on the tumor site, this approach offers the potential for enhanced therapeutic efficacy and reduced systemic toxicity.

REFERENCES

1. Khan, Y., & Han, D. K. (2013). "Recent advancements in polymeric drug delivery systems for cancer therapy." *Journal of Drug Delivery Science and Technology*, 23(3), 239-246.

2. Khan, M. Y., & Bajaj, M. (2012). "Polymeric nanoparticles for oral delivery of drugs targeting the colon." *Pharmaceutical Research*, 29(7), 1880-1892.

3. Patel, V., & Nair, A. (2011). "Polymeric micelles for targeted drug delivery in cancer therapy." *Journal of Controlled Release*, 149(3), 310-318.

4. Sharma, A., & Gupta, V. (2010). "Colonic drug delivery systems: An overview." *Asian Journal of Pharmaceutical Sciences*, 5(2), 93-106.

5. Yadav, V. S., & Singh, N. (2009). "Advances in targeting ligands for drug delivery in cancer therapy." *Journal of Nanoscience and Nanotechnology*, 9(12), 6905-6915.

6. Huang, Y., & Zhang, L. (2008). "Development of folic acid-conjugated nanoparticles for targeted drug delivery in colorectal cancer." *Nanomedicine: Nanotechnology, Biology and Medicine*, 4(3), 257-265.

7. Zhang, M., & Wang, Y. (2007). "Polymeric microparticles for colon-specific drug delivery." *Drug Development and Industrial Pharmacy*, 33(6), 597-606.

8. Lee, J. Y., & Lee, J. W. (2006). "Controlled release of anticancer drugs from polymeric microspheres: A study on in vitro and in vivo performances." *European Journal of Pharmaceutics and Biopharmaceutics*, 62(2), 214-220.

9. Ravi Kumar, M. N. V., & Karthikeyan, K. (2005). "Targeted drug delivery systems: New approaches in cancer therapy." *Drug Delivery*, 12(4), 175-183.

10. Nasseri, M. B., & Sun, T. (2004). "Advancements in the development of polymer-based drug delivery systems for cancer therapy." *Journal of Controlled Release*, 98(2), 243-261.